FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Tim Crook

Research Profile

Chemicals & Drugs

Physiology

Living Beings

Papillomaviridae

Disorders

Genes & Molecular Sequences

Anatomy

Concepts & Ideas

Molecular Sequence Data

Co-author Network

Publications

TOP 3
Cristiana Lo Nigro; Charlotte Proby; Nelofer Syed; Alastair Thompson; Hexiao Wang; Evangelos Briasoulis; Alan Evans; Colin Fleming; C Harwood; Eleftheria Hatzimichael; Gareth J Inman; Laura Lattanzio; Irene Leigh; Rubeta Matin; Angela McHugh; Marco Merlano; Tim Crook
Methylated Tissue Factor Pathway Inhibitor 2 (TFPI2) DNA in Serum Is a Biomarker of Metastatic Melanoma.
Nelofer Syed; Peter W Szlosarek; M Awad; J Bomalaski; H M Coley; Eleftheria C Hatzimichael; K Janczar; J Langer; L Lattanzio; C Lo Nigro; K O'Neil; F Roncaroli; P Singh; Tim Crook
Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma.
Eleftheria C Hatzimichael; K Janczar; L E Karran; L Lattanzio; C Lo Nigro; M Merlano; M Monteverde; Alexandra Papoudou-Bai; P Schmid; R Shah; Justin Stebbing; Nelofer Syed; A Thompson; Daniela Vivenza; Maria Bai; M Bower; Evangelos Briasoulis; Aggeliki Dasoula; M J S Dyer; C ElguetaKarstegl; P J Farrell; Tim Crook
The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Tim Crook (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Cristiana Lo Nigro; Charlotte Proby; Nelofer Syed; Alastair Thompson; Hexiao Wang; Evangelos Briasoulis; Alan Evans; Colin Fleming; C Harwood; Eleftheria Hatzimichael; Gareth J Inman; Laura Lattanzio; Irene Leigh; Rubeta Matin; Angela McHugh; Marco Merlano; Tim Crook
Methylated Tissue Factor Pathway Inhibitor 2 (TFPI2) DNA in Serum Is a Biomarker of Metastatic Melanoma.
The Journal of investigative dermatology 2013;133(5):1278-85.
2013: Nelofer Syed; Peter W Szlosarek; M Awad; J Bomalaski; H M Coley; Eleftheria C Hatzimichael; K Janczar; J Langer; L Lattanzio; C Lo Nigro; K O'Neil; F Roncaroli; P Singh; Tim Crook
Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma.
Cell death & disease 2013;4():e458.
2012: Eleftheria C Hatzimichael; K Janczar; L E Karran; L Lattanzio; C Lo Nigro; M Merlano; M Monteverde; Alexandra Papoudou-Bai; P Schmid; R Shah; Justin Stebbing; Nelofer Syed; A Thompson; Daniela Vivenza; Maria Bai; M Bower; Evangelos Briasoulis; Aggeliki Dasoula; M J S Dyer; C ElguetaKarstegl; P J Farrell; Tim Crook
The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma.
British journal of cancer 2012;107(8):1423-32.
2012: Eleftheria C Hatzimichael; Valentinos Kounnis; Laura Lattanzio; Alexandra Papoudou-Bai; Cristiana Lo Nigro; Leonidas Benetatos; Evangelos Briasoulis; Aggeliki Dasoula; George Dranitsaris; Tim Crook
Bcl2-interacting killer CpG methylation in multiple myeloma: a potential predictor of relapsed/refractory disease with therapeutic implications.
Leukemia & lymphoma 2012;53(9):1709-13.
2012: Daniela Vivenza; Ida Colantonio; Alberto Comino; Tim Crook; Nerina Denaro; Milena Gasco; Laura Lattanzio; Marco Merlano; Martino Monteverde; Guido Natoli; Elvio Russi; Nelofer Syed; Cristiana Lo Nigro
MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer.
Oral oncology 2012;48(7):602-7.
2012: C Lo Nigro; A McHugh; Marco Merlano; M Monteverde; C Palmieri; C Proby; P Quinlan; Nelofer Syed; A Thompson; Daniela Vivenza; H Wang; O Garrone; O Gojis; E Hatzimichael; L Jordan; L Lattanzio; S Lee; E Briasoulis; Alberto Comino; Tim Crook
NT5E CpG island methylation is a favourable breast cancer biomarker.
British journal of cancer 2012;107(1):75-83.
2012: Chara Stavraka; Roshan Agarwal; Tim Crook; Amy Ford; Hani Gabra; Sadaf Ghaem-Maghami; Sarah Blagden
A study of symptoms described by ovarian cancer survivors.
Gynecologic oncology 2012;125(1):59-64.
2012: B Delage; Jude Fitzgibbon; J Gribben; Eleftheria C Hatzimichael; Simon P Joel; Nick Lemoine; C-F Li; P Luong; Lenushka Maharaj; T J Mitchell; C O'Riain; Alexandra Papoudou-Bai; Nelofer Syed; J Bomalaski; R Cerio; L-T Chen; Tim Crook; S J Whittaker; Peter W Szlosarek
Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis.
Cell death & disease 2012;3():e342.
2011: Javier E Girardini; Lee Jordan; Guillermina Lozano; Miguel Mano; Carolina Marotta; Anthony R Means; Marco Napoli; Silvano Piazza; Phil Quinlan; Enrico Radaelli; Antonio Rosato; Alessandra Rustighi; Eugenio Scanziani; Claudio Schneider; Alastair Thompson; Valeria Capaci; Tim Crook; Giannino Del Sal
A Pin1/mutant p53 axis promotes aggressiveness in breast cancer.
Cancer cell 2011;20(1):79-91.
2011: Nelofer Syed; Peter Szlosarek; Sarah P Blagden; Helen M Coley; Eleftheria Hatzimichael; Dominique Koensgen; David P Lovell; Iain McNeish; Alexander Mustea; Peter Schmid; Jalid Sehouli; Tim Crook
Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer.
Cancer research 2011;71(9):3317-27.
2011: L A Henry; D A Johnson; D Sarrió; S Lee; P R Quinlan; Tim Crook; A M Thompson; Jorge S Reis-Filho; Clare M Isacke
Endoglin expression in breast tumor cells suppresses invasion and metastasis and correlates with improved clinical outcome.
Oncogene 2011;30(9):1046-58.
2010: Adèle Hannigan; Paul Smith; Gabriela Kalna; Cristiana Lo Nigro; Clare Orange; Darren I O'Brien; Reshma Shah; Nelofer Syed; Lindsay C Spender; Blanca Herrera; Johanna K Thurlow; Laura Lattanzio; Martino Monteverde; Meghan E Maurer; Francesca M Buffa; Jelena Mann; Chung (David) K. Chu; Catharine M L West; Max Patridge; Karin A Oien; Jonathan A Cooper; Margaret C Frame; Adrian L Harris; Louise Hiller; Linda J Nicholson; Milena Gasco; Tim Crook; Gareth J Inman
Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter.
The Journal of clinical investigation 2010;120(8):2842-57.
2010: S Lee; N Syed; J Taylor; Paul Smith; B Griffin; M Baens; M Bai; K Bourantas; J Stebbing; K Naresh; M Nelson; M Tuthill; mark bower; E Hatzimichael; Tim Crook
DUSP16 is an epigenetically regulated determinant of JNK signalling in Burkitt's lymphoma.
British journal of cancer 2010;103(2):265-74.
2010: Barbara Delage; Dean A Fennell; Linda Nicholson; Iain McNeish; Nick Lemoine; Tim Crook; Peter W Szlosarek
Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer.
International journal of cancer. Journal international du cancer 2010;126(12):2762-72.
2009: R Shah; Paul Smith; C Purdie; P Quinlan; Laurence H Baker; P Aman; A M Thompson; Tim Crook
The prolyl 3-hydroxylases P3H2 and P3H3 are novel targets for epigenetic silencing in breast cancer.
British journal of cancer 2009;100(10):1687-96.
2009: J Lopez; M Percharde; Helen M Coley; Andrew Webb; Tim Crook
The context and potential of epigenetics in oncology.
British journal of cancer 2009;100(4):571-7.
2008: Sanne Martens-de Kemp; Nicholas C Turner; Richard Elliott; Nelofer Syed; Ornella Garrone; Milena Gasco; Andrew Tutt; Tim Crook; christopher Lord; Alan Ashworth
Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer.
Cancer cell 2008;13(2):91-104.
2008: E Anderton; J Yee; Paul Smith; Tim Crook; R E White; Martin J Allday
Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma.
Oncogene 2008;27(4):421-33.
2007: Fiamma Mantovani; Francesca Tocco; Javier E Girardini; Paul Smith; Milena Gasco; Xin Lu; Tim Crook; Giannino Del Sal
The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP.
Nature structural & molecular biology 2007;14(10):912-20.
2007: Chiara Gorrini; Massimo Squatrito; Chiara Luise; Nelofer Syed; Daniele Perna; Landon Wark; Francesca Martinato; Domenico Sardella; Alessandro Verrecchia; Samantha Bennett; Stefano Confalonieri; matteo cesaroni; Francesco Marchesi; Milena Gasco; Eugenio Scanziani; Maria Capra; Sabine Mai; Paolo Giovanni Nuciforo; Tim Crook; John Lough; Bruno Amati
Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response.
Nature 2007;448(7157):1063-7.
2007: Paul Smith; Linda J Nicholson; Nelofer Syed; Annette Payne; Louise Hiller; Ornella Garrone; Marcella Occelli; Milena Gasco; Tim Crook
Epigenetic inactivation implies independent functions for insulin-like growth factor binding protein (IGFBP)-related protein 1 and the related IGFBPL1 in inhibiting breast cancer phenotypes.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(14):4061-8.
2006: Daniele Bergamaschi; Yardena Samuels; Alexandra Sullivan; Marketa Zvelebil; Hilde Breyssens; Andrea Bisso; Giannino Del Sal; Nelofer Syed; Paul Smith; Milena Gasco; Tim Crook; Xin Lu
iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53.
Nature genetics 2006;38(10):1133-41.
2006: Diane Crighton; Simon Wilkinson; Jim O'Prey; Nelofer Syed; Paul Smith; Paul R Harrison; Milena Gasco; Ornella Garrone; Tim Crook; Kevin M Ryan
DRAM, a p53-induced modulator of autophagy, is critical for apoptosis.
Cell 2006;126(1):121-34.
2006: Justin Stebbing; mark bower; Nelofer Syed; Paul Smith; Veronica Yu; Tim Crook
Epigenetics: an emerging technology in the diagnosis and treatment of cancer.
Pharmacogenomics 2006;7(5):747-57.
2006: Paul Smith; Nelofer Syed; Tim Crook
Epigenetic inactivation implies a tumor suppressor function in hematologic malignancies for Polo-like kinase 2 but not Polo-like kinase 3.
Cell cycle (Georgetown, Tex.) 2006;5(12):1262-4.
2006: Nelofer Syed; Paul Smith; Alexandra Sullivan; Lindsay C Spender; Martin Dyer; Lorraine Karran; Jenny O'nions; Martin J Allday; Ingrid Hoffmann; Dorothy Crawford; Beverley Griffin; Paul J Farrell; Tim Crook
Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies.
Blood 2006;107(1):250-6.
2004: Damian Yap; Jung-Kuang Hsieh; Shan Zhong; Victoria Heath; Barry A Gusterson; Tim Crook; Xin Lu
Ser392 phosphorylation regulates the oncogenic function of mutant p53.
Cancer research 2004;64(14):4749-54.
2004: Victoria L Brown; Catherine A Harwood; Tim Crook; James G Cronin; David P Kelsell; Charlotte M Proby
p16INK4a and p14ARF tumor suppressor genes are commonly inactivated in cutaneous squamous cell carcinoma.
The Journal of investigative dermatology 2004;122(5):1284-92.
2004: Alexandra Sullivan; Nelofer Syed; Milena Gasco; Daniele Bergamaschi; Giuseppe Trigiante; Marlene Attard; Louise Hiller; Paul J Farrell; Paul Smith; Xin Lu; Tim Crook
Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo.
Oncogene 2004;23(19):3328-37.
2004: Daniele Bergamaschi; Yardena Samuels; Boquan Jin; Sai Duraisingham; Tim Crook; Xin Lu
ASPP1 and ASPP2: common activators of p53 family members.
Molecular and cellular biology 2004;24(3):1341-50.
2003: Milena Gasco; Tim Crook
p53 family members and chemoresistance in cancer: what we know and what we need to know.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2003;6(6):323-8.
2003: Peter Osin; Yong-Jie Lu; J Stone; Tim Crook; R S Houlston; Milena Gasco; Barry A Gusterson; Janet Shipley
Distinct genetic and epigenetic changes in medullary breast cancer.
International journal of surgical pathology 2003;11(3):153-8.
2003: Daniele Bergamaschi; Milena Gasco; Louise Hiller; Alexandra Sullivan; Nelofer Syed; Giuseppe Trigiante; Isik G Yulug; Marco Merlano; Gianmauro Numico; Alberto Comino; Marlene Attard; Olivier Reelfs; Barry A Gusterson; Alexandra K Bell; Victoria Heath; Mahvash Tavassoli; Paul J Farrell; Paul Smith; Xin Lu; Tim Crook
p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis.
Cancer cell 2003;3(4):387-402.
2003: Milena Gasco; Isik G Yulug; Tim Crook
TP53 mutations in familial breast cancer: functional aspects.
Human mutation 2003;21(3):301-6.
2003: Daniele Bergamaschi; Yardena Samuels; Nigel J O'Neil; Giuseppe Trigiante; Tim Crook; Jung-Kuang Hsieh; Daniel J O'Connor; Shan Zhong; Isabelle Campargue; Matthew L Tomlinson; Patricia E Kuwabara; Xin Lu
iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human.
Nature genetics 2003;33(2):162-7.
2002: Arzu Atalay; Tim Crook; Mehmet Ozturk; Isik G Yulug
Identification of genes induced by BRCA1 in breast cancer cells.
Biochemical and biophysical research communications 2002;299(5):839-46.
2002: Mark Hickabottom; Gillian A Parker; Paul S Freemont; Tim Crook; Martin J Allday
Two nonconsensus sites in the Epstein-Barr virus oncoprotein EBNA3A cooperate to bind the co-repressor carboxyl-terminal-binding protein (CtBP).
The Journal of biological chemistry 2002;277(49):47197-204.
2002: Jane M McGregor; Catherine A Harwood; Louise Brooks; Sheila A Fisher; Deirdre A Kelly; Jenny O'nions; Antony R Young; Thirunavukarasu Surentheran; Judith Breuer; Thomas P Millard; Cathryn M Lewis; Irene M Leigh; Alan Storey; Tim Crook
Relationship between p53 codon 72 polymorphism and susceptibility to sunburn and skin cancer.
The Journal of investigative dermatology 2002;119(1):84-90.
2002: Milena Gasco; Alexandra K Bell; Victoria Heath; Alexandra Sullivan; Paul Smith; Louise Hiller; Isik G Yulug; Gianmauro Numico; Marco Merlano; Paul J Farrell; Mahvash Tavassoli; Barry A Gusterson; Tim Crook
Epigenetic inactivation of 14-3-3 sigma in oral carcinoma: association with p16(INK4a) silencing and human papillomavirus negativity.
Cancer research 2002;62(7):2072-6.
2002: Milena Gasco; Alexandra Sullivan; Claire Repellin; Louise Brooks; Paul J Farrell; John Tidy; Barbara Dunne; Barry A Gusterson; David J Evans; Tim Crook
Coincident inactivation of 14-3-3sigma and p16INK4a is an early event in vulval squamous neoplasia.
Oncogene 2002;21(12):1876-81.
2002: Archana Reddy; Martin Yuille; Alexandra Sullivan; Claire Repellin; Alexandra Bell; John Tidy; David J Evans; Paul J Farrell; Barry A Gusterson; Milena Gasco; Tim Crook
Analysis of CHK2 in vulval neoplasia.
British journal of cancer 2002;86(5):756-60.
2002: Alexandra Sullivan; Martin Yuille; Claire Repellin; Archana Reddy; Olivier Reelfs; Alexandra Bell; Barbara Dunne; Barry A Gusterson; Peter Osin; Paul J Farrell; Isik G Yulug; Abigail Evans; Tayfun Ozcelik; Milena Gasco; Tim Crook
Concomitant inactivation of p53 and Chk2 in breast cancer.
Oncogene 2002;21(9):1316-24.
2002: LA Brooks; Alexandra Sullivan; Jenny O'nions; Alexandra Bell; Barbara Dunne; John Tidy; David J Evans; Peter Osin; K H Vousden; Barry A Gusterson; Paul J Farrell; Alan Storey; Milena Gasco; T Sakai; Tim Crook
E7 proteins from oncogenic human papillomavirus types transactivate p73: role in cervical intraepithelial neoplasia.
British journal of cancer 2002;86(2):263-8.
2001: Jenny O'nions; LA Brooks; Alexandra Sullivan; Alexandra Bell; Barbara Dunne; M Rozycka; Archana Reddy; John Tidy; D Evans; Paul J Farrell; A Evans; Milena Gasco; Barry A Gusterson; Tim Crook
p73 is over-expressed in vulval cancer principally as the Delta 2 isoform.
British journal of cancer 2001;85(10):1551-6.
2001: Elisabeth Fraser-Andrews; Jane M McGregor; Tim Crook; L Brookes; Eduardo Calonje; Sean J Whittaker
Sézary syndrome with a complex, frameshift p53 gene mutation in a Chernobyl survivor.
Clinical and experimental dermatology 2001;26(8):683-5.
2001: Y Samuels-Lev; Daniel J O'Connor; Daniele Bergamaschi; Giuseppe Trigiante; Jung-Kuang Hsieh; Shan Zhong; I Campargue; Louie Naumovski; Tim Crook; Xin Lu
ASPP proteins specifically stimulate the apoptotic function of p53.
Molecular cell 2001;8(4):781-94.
2001: Robert Touitou; M Hickabottom; G Parker; Tim Crook; Martin J Allday
Physical and functional interactions between the corepressor CtBP and the Epstein-Barr virus nuclear antigen EBNA3C.
Journal of virology 2001;75(16):7749-55.
2000: LA Brooks; John Tidy; Barry A Gusterson; Louise Hiller; Jenny O'nions; Milena Gasco; Maria Carmen Marin; Paul J Farrell; William G Kaelin; Tim Crook
Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus.
Cancer research 2000;60(24):6875-7.
2000: Tim Crook; J M Nicholls; Louise Brooks; Jenny O'nions; Martin J Allday
High level expression of deltaN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)?
Oncogene 2000;19(30):3439-44.
2000: Maria Carmen Marin; CA Jost; LA Brooks; Meredith S. Irwin; Jenny O'nions; John Tidy; Nicholas James; J M McGregor; Catherine A Harwood; Isik G Yulug; K H Vousden; Martin J Allday; B Gusterson; S Ikawa; Philip W Hinds; Tim Crook; William G Kaelin
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour.
Nature genetics 2000;25(1):47-54.
1999: P D Smith; S Crossland; G Parker; Peter Osin; Louise Brooks; J Waller; E Philp; MR Crompton; Barry A Gusterson; Martin J Allday; Tim Crook
Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions.
Oncogene 1999;18(15):2451-9.
1999: Jane M McGregor; Tim Crook; Elisabeth Fraser-Andrews; M Rozycka; S Crossland; Louise Brooks; Sean J Whittaker
Spectrum of p53 gene mutations suggests a possible role for ultraviolet radiation in the pathogenesis of advanced cutaneous lymphomas.
The Journal of investigative dermatology 1999;112(3):317-21.
1999: TG Willis; Dalal M Jadayel; Ming-Qing Du; H Peng; AR Perry; M Abdul-Rauf; Helen Price; Lorraine Karran; O Majekodunmi; I Wlodarska; L Pan; Tim Crook; Rifat A Hamoudi; Peter G Isaacson; Martin J S Dyer
Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types.
Cell 1999;96(1):35-45.
1998: Peter Osin; Barry A Gusterson; E Philp; J Waller; J Bartek; Julian Peto; Tim Crook
Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers.
European journal of cancer (Oxford, England : 1990) 1998;34(11):1683-6.
1998: Tim Crook; LA Brooks; S Crossland; Peter Osin; Karen T Barker; J Waller; E Philp; P D Smith; Isik G Yulug; Julian Peto; G Parker; Martin J Allday; MR Crompton; Barry A Gusterson
p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours.
Oncogene 1998;17(13):1681-9.
1998: Peter Osin; Tim Crook; T Powles; Julian Peto; Barry A Gusterson
Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers.
Lancet 1998;351(9114):1487.
1998: Tim Crook; Gillian A Parker; M Rozycka; S Crossland; Martin J Allday
A transforming p53 mutant, which binds DNA, transactivates and induces apoptosis reveals a nuclear:cytoplasmic shuttling defect.
Oncogene 1998;16(11):1429-41.
1998: Peter Osin; Janet Shipley; Y J Lu; Tim Crook; Barry A Gusterson
Experimental pathology and breast cancer genetics: new technologies.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1998;152():35-48.
1997: Jane M McGregor; Ron J M Berkhout; M Rozycka; Jan ter Schegget; Jan N Bouwes Bavinck; Louise Brooks; Tim Crook
p53 mutations implicate sunlight in post-transplant skin cancer irrespective of human papillomavirus status.
Oncogene 1997;15(14):1737-40.
1997: Tim Crook; S Crossland; MR Crompton; Peter Osin; Barry A Gusterson
p53 mutations in BRCA1-associated familial breast cancer.
Lancet 1997;350(9078):638-9.
1997: LA Brooks; A J Wilson; Tim Crook
Kaposi's sarcoma-associated herpesvirus (KSHV)/human herpesvirus 8 (HHV8)--a new human tumour virus.
The Journal of pathology 1997;182(3):262-5.
1997: Daniela Lens; PJ De Schouwer; Rifat A Hamoudi; M Abdul-Rauf; Nahla farahat; Estella Matutes; Tim Crook; Martin J S Dyer; Daniel Catovsky
p53 abnormalities in B-cell prolymphocytic leukemia.
Blood 1997;89(6):2015-23.
1996: G A Parker; Tim Crook; M Bain; E A Sara; Paul J Farrell; Martin J Allday
Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7.
Oncogene 1996;13(12):2541-9.
1996: Tim Crook; Robert L Ludwig; N J Marston; D Willkomm; Karen H Vousden
Sensitivity of p53 lysine mutants to ubiquitin-directed degradation targeted by human papillomavirus E6.
Virology 1996;217(1):285-92.
1995: J D Morris; A L Eddleston; Tim Crook
Viral infection and cancer.
Lancet 1995;346(8977):754-8.
1994: Tim Crook; N J Marston; E A Sara; Karen H Vousden
Transcriptional activation by p53 correlates with suppression of growth but not transformation.
Cell 1994;79(5):817-27.
1994: N J Marston; Tim Crook; Karen H Vousden
Interaction of p53 with MDM2 is independent of E6 and does not mediate wild type transformation suppressor function.
Oncogene 1994;9(9):2707-16.
1994: Tim Crook; C Fisher; P J Masterson; Karen H Vousden
Modulation of transcriptional regulatory properties of p53 by HPV E6.
Oncogene 1994;9(4):1225-30.
1994: Eric W-F Lam; J D Morris; R Davies; Tim Crook; Roger J Watson; Karen H Vousden
HPV16 E7 oncoprotein deregulates B-myb expression: correlation with targeting of p107/E2F complexes.
The EMBO journal 1994;13(4):871-8.
1994: Tim Crook; Karen H Vousden
Interaction of HPV E6 with p53 and associated proteins.
Biochemical Society transactions 1994;22(1):52-5.
1993: Karen H Vousden; Tim Crook; Paul J Farrell
Biological activities of p53 mutants in Burkitt's lymphoma cells.
The Journal of general virology 1993;74 ( Pt 5)():803-10.
1993: R Davies; R Hicks; Tim Crook; J Morris; Karen H Vousden
Human papillomavirus type 16 E7 associates with a histone H1 kinase and with p107 through sequences necessary for transformation.
Journal of virology 1993;67(5):2521-8.
1993: J D Morris; Tim Crook; L R Bandara; R Davies; N B LaThangue; Karen H Vousden
Human papillomavirus type 16 E7 regulates E2F and contributes to mitogenic signalling.
Oncogene 1993;8(4):893-8.
1992: Tim Crook; Karen H Vousden
Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens.
The EMBO journal 1992;11(11):3935-40.
1992: Tim Crook; D Wrede; J A Tidy; W P Mason; D J Evans; Karen H Vousden
Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours.
Lancet 1992;339(8801):1070-3.
1991: Tim Crook; J A Tidy; Karen H Vousden
Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation.
Cell 1991;67(3):547-56.
1991: Paul J Farrell; G J Allan; F Shanahan; Karen H Vousden; Tim Crook
p53 is frequently mutated in Burkitt's lymphoma cell lines.
The EMBO journal 1991;10(10):2879-87.
1991: Tim Crook; D Wrede; J Tidy; J Scholefield; L Crawford; Karen H Vousden
Status of c-myc, p53 and retinoblastoma genes in human papillomavirus positive and negative squamous cell carcinomas of the anus.
Oncogene 1991;6(7):1251-7.
1991: Tim Crook; D Wrede; Karen H Vousden
p53 point mutation in HPV negative human cervical carcinoma cell lines.
Oncogene 1991;6(5):873-5.
1991: Tim Crook; C Fisher; Karen H Vousden
Modulation of immortalizing properties of human papillomavirus type 16 E7 by p53 expression.
Journal of virology 1991;65(1):505-10.
1991: D Wrede; J A Tidy; Tim Crook; D Lane; Karen H Vousden
Expression of RB and p53 proteins in HPV-positive and HPV-negative cervical carcinoma cell lines.
Molecular carcinogenesis 1991;4(3):171-5.
1990: L Banks; S C Barnett; Tim Crook
HPV-16 E7 functions at the G1 to S phase transition in the cell cycle.
Oncogene 1990;5(6):833-7.